Chonluten

Overview

Chonluten is a synthetic tripeptide — Glu-Asp-Gly (EDG, L-glutamyl-L-aspartyl-glycine) — from Vladimir Khavinson's "short peptide bioregulator" school at the St. Petersburg Institute of Bioregulation and Gerontology. It is framed as a tissue-specific "cytogen" meant to support bronchial and lung tissue, and is sold in Russia as an over-the-counter peptide bioregulator capsule.

The chemistry is well-defined and verifiable (PubChem CID 194641; CAS 75007-24-8; formula C11H17N3O8; molecular weight 319.27 g/mol; also called the T-34 tripeptide). The biology, however, is thin. The strongest verifiable evidence is a single in-vitro study (Avolio et al., Int J Mol Sci 2022, with Khavinson as a co-author) in which Chonluten — among several Khavinson peptides — reduced LPS-stimulated TNF and IL-6 in human THP-1 monocyte/macrophage cells and altered proliferation/apoptosis and extracellular-vesicle output. The Russian clinical claims (COPD, chronic bronchitis, respiratory support in the elderly) are uncontrolled, from the originating group, and not independently replicated — they should be read as claimed/marketing, not established efficacy. That mixed picture — real, defined chemistry but weak, single-lineage biology — is why it is filed here as disputed.

Chemistry and structure

Values above are drawn from PubChem CID 194641, whose synonyms include CAS 75007-24-8 and the name "T-34 tripeptide." Two caveats: PubChem's record does not itself list the trade name "Chonluten," so the Chonluten = Glu-Asp-Gly identity is asserted by vendors and by the Avolio (2022) paper, not by the chemistry database. And the stereochemistry / exact salt form of commercially sold "Chonluten" material has not been verified against a reference standard here.

Mechanism of action

• Class-level "peptide-DNA" transcriptional regulation — the Khavinson framework proposes that such short peptides penetrate cell and nuclear membranes and bind specific DNA/promoter regions to modulate tissue-specific gene expression (an epigenetic-style mechanism) rather than acting via classical receptors. [Hypothesis] — a class-level theoretical framework, not experimentally established for Glu-Asp-Gly specifically. (Khavinson-school framing.)
• Reduced pro-inflammatory cytokines — in terminally differentiated human THP-1 macrophages, Chonluten reduced LPS-stimulated expression/secretion of TNF and IL-6, associated with attenuated inflammatory signalling / immunological tolerance. [In vitro] (Avolio et al., Int J Mol Sci 2022; PMC8999041 — human cell line, not animal or human in vivo.)
• Altered proliferation and apoptosis, and increased extracellular-vesicle output — in THP-1 monocytes/macrophages, Chonluten increased cell growth while simultaneously raising apoptosis and increased extracellular-vesicle production, behaving distinctively versus other tested peptides. [In vitro] (Same 2022 study.)
• Tissue-specific regulation of genes such as c-Fos, HSP70, SOD, COX-2, TNF-alpha in lung/GI tissue — stated on commercial sites. [Hypothesis] — primary-source verification was not located; treat as unverified vendor claim. (Commercial listings.)

Research and evidence

Human evidence. There are no randomised controlled human trials of the synthetic Glu-Asp-Gly tripeptide in the indexed peer-reviewed literature. Russian-language sources and vendors claim clinical use in COPD, chronic bronchitis, and respiratory support in the elderly, but these observations are uncontrolled, originate from the developing institute (Khavinson group), and have not been independently replicated. All human-benefit claims should be read as unverified marketing / claimed-clinical, not established efficacy. In short: no well-established human clinical trials. Human pharmacokinetics (half-life, bioavailability), safety/toxicology, and any validated dosing are not established in primary sources — vendor "protocols" are not clinically validated.

Status and regulation

Chonluten is not FDA- or EMA-approved for any indication and is not a licensed medicine in the US, EU, UK, or comparable jurisdictions. In the Russian Federation it is distributed as a peptide bioregulator / dietary-supplement-class "cytogen" by the originating institute and resellers — a national marketing status that is not equivalent to a stringent-regulator approval and has not been independently evaluated for efficacy or safety. In Western markets it is offered explicitly "for research use only." Being intended for human use would make it an unauthorised (unlicensed) medicine in FDA/EMA jurisdictions. This is a regulatory classification, not a statement that it is safe or legal to take.

WADA status: not established in any source found — it is neither assumed prohibited nor assumed permitted. WADA sport-prohibition is a separate axis from legality, and non-approval must not be read as an automatic S0 classification.

Safety

• Human safety/toxicology profile is not established in primary sources — no adequate pharmacokinetic, toxicology, or adverse-event data were found.
• The strongest reported biology is in-vitro (a human cell line); cell-culture effects do not establish safety in humans, and the clinical claims are uncontrolled and unreplicated.
• Material sold as a research reagent is not a quality-controlled medicine and may vary in identity, purity, stereochemistry, salt form, and sterility.
• No validated human dosing exists; vendor "protocols" (~200–400 mcg oral courses) are not clinically validated, and any human use is experimental by design.

Legal status

Chonluten's regulatory classification is a research reagent ("research use only") in the US and EU — it is not approved for human use. A Russian "cytogen"/bioregulator listing is a national marketing decision and is not affirmative permission elsewhere: "no specific ban" is not authorisation, and a compound becomes an unauthorised medicine the moment it is intended for human use, regardless of how it is labelled at point of sale. WADA sport-prohibition is a separate axis from legality, and no source asserts a WADA class code for this compound, so none is stated here. Regulatory status differs by country and can change. This is not legal advice — verify the status in your own jurisdiction. (Dated 2026-07-08.)

How it compares

• Epitalon — another Khavinson "short peptide bioregulator" (a synthetic tetrapeptide) marketed for longevity; it shares Chonluten's pattern of bold tissue-specific claims resting largely on a single research lineage with limited independent replication.
• Thymalin — a multi-peptide calf-thymus extract from the same Khavinson school; the 2022 THP-1 study that supports Chonluten tested several of these peptides together. They share the pattern of limited, single-lineage evidence.

Common misconceptions

• "Chonluten is a proven lung/COPD treatment." No. The respiratory claims are uncontrolled, single-group Russian observations [Human — unverified]; the only peer-reviewed data are in-vitro [In vitro]. There is no well-established human trial.
• "PubChem confirms it's called Chonluten." Not exactly — PubChem CID 194641 lists CAS 75007-24-8 and 'T-34 tripeptide' but not the trade name 'Chonluten.' The Chonluten = EDG identity comes from vendors and the Avolio (2022) paper, not the chemistry database.
• "Chonluten is the same as Bronchogen." No. Bronchogen is a different Khavinson lung peptide (Ala-Glu-Asp-Leu / AEDL tetrapeptide). Chonluten is the Glu-Asp-Gly tripeptide.
• "It reprograms lung genes." The peptide-DNA transcription mechanism is a class-level hypothesis [Hypothesis] from the developers' group — not established for Glu-Asp-Gly specifically, and the specific-gene claims (c-Fos, HSP70, SOD, COX-2) are unverified vendor statements.
• "Not banned means legal to take." No specific ban is not affirmative permission; Chonluten is a research reagent and becomes an unauthorised medicine the moment it is intended for human use.